Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Pat Growth 25pctExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹276.00

prior close

₹274.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+0.8% vs market

Pharmaceuticals peers, median of 162sector+0.0%+1.5% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-0.9

15m

+0.8

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.7+0.8+0.0+1.5

Next day

+4.0+0.9+3.1+0.4+3.6

+0.3+0.6-0.3+0.0+0.3

+5.4-0.8+6.2-0.6+6.1

+2.5-0.4+2.9-0.1+2.6

+4.7+0.2+4.5+0.9+3.9

+9.1+1.4+7.6+0.7+8.4

15d

+64.3+4.2+60.1+0.9+63.3

+59.4+6.3+53.1+2.6+56.9

+92.0+11.3+80.7+6.2+85.9

+86.2+14.0+72.3+8.9+77.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bliss GVS Pharma Limited reported strong financial performance for FY26 ended March 31, 2026. Standalone net profit grew 47.55% to Rs. 9,687.44 lakh from Rs. 6,565.87 lakh in FY25, while consolidated net profit increased 22.96% to Rs. 10,078.12 lakh from Rs. 8,195.91 lakh. Total standalone income rose to Rs. 70,342.41 lakh and consolidated income reached Rs. 84,621.91 lakh. The Board declared a 100% final dividend (Rs. 1 per share) subject to shareholder approval. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated financial results. Two new subsidiaries were incorporated in Kenya and Democratic Republic of Congo during the year.

Likely market impact

Strong profit growth signals improved operational efficiency. The clean audit opinion and consistent dividend payments indicate financial stability, which should be positive for shareholder confidence and the stock price.